Items where Author is "Krahenbuhl, S."

2016

Neumair, P. and Joos, L. and Warschkow, R. and Ess, S. and Hitz, F. and Frueh, M. and Brutsche, M. H. and Baty, F. and Krahenbuhl, S. and Jorger, M.. (2016) 169P: Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study. Journal of Thoracic Oncology, 11 (4 Suppl). p. 131.

Berger, B. and Donzelli, M. and Maseneni, S. and Boess, F. and Roth, A. and Krahenbuhl, S. and Haschke, M.. (2016) Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail. Front Pharmacol, 7. p. 443.

Derungs, A. and Donzelli, M. and Berger, B. and Noppen, C. and Krahenbuhl, S. and Haschke, M.. (2016) Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study. Clin Pharmacokinet, 55 (1). pp. 79-91.

Neumair, P. and Joos, L. and Warschkow, R. and Dutly, A. and Ess, S. and Hitz, F. and Fruh, M. and Brutsche, M. and Baty, F. and Krahenbuhl, S. and Cerny, T. and Joerger, M.. (2016) Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer, 100. pp. 38-44.

Krahenbuhl, S. and Pavik-Mezzour, I. and von Eckardstein, A.. (2016) Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs, 76 (12). pp. 1175-1190.

2013

Hirzel, E. and Lindinger, P. W. and Maseneni, S. and Giese, M. and Rhein, V. V. and Eckert, A. and Hoch, M. and Krahenbuhl, S. and Eberle, A. N.. (2013) Differential modulation of ROS signals and other mitochondrial parameters by the antioxidants MitoQ, resveratrol and curcumin in human adipocytes. Journal of receptors and signal transduction, Vol. 33, H. 5. pp. 304-312.

2012

Pham, T. T. T. and See, H. H. and Morand, R. and Krahenbuhl, S. and Hauser, P. C.. (2012) Determination of free and total valproic acid in human plasma by capillary electrophoresis with contactless conductivity detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Vol. 907. pp. 74-78.

Hysek, C. M. and Simmler, L. D. and Nicola, V. G. and Vischer, N. and Donzelli, M. and Krahenbuhl, S. and Grouzmann, E. and Huwyler, J. and Hoener, M. C. and Liechti, M. E.. (2012) Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE, Vol. 7, H. 5 , e36476.

Morand, R. and Todesco, L. and Donzelli, M. and Fischer-Barnicol, D. and Mullen, P. J. and Krahenbuhl, S.. (2012) Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. Therapeutic drug monitoring, Vol. 34, H. 4. pp. 406-414.

2010

Egger, S. S. and Meier, S. and Leu, C. and Christen, S. and Gratwohl, A. and Krahenbuhl, S. and Haschke, M.. (2010) Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone marrow transplantation, Vol. 45, H. 7. pp. 1197-1203.

Haschke, M. and Vitins, T. and Lude, S. and Todesco, L. and Novakova, K. and Herrmann, R. and Krahenbuhl, S.. (2010) Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrology, dialysis, transplantation, Vol. 25, H. 2. pp. 426-433.

2009

Pormsila, W. and Krahenbuhl, S. and Hauser, P. C.. (2009) Capillary electrophoresis with contactless conductivity detection for uric acid determination in biological fluids. Analytica Chimica Acta, Vol. 636, pp. 224-228.

Sidharta, P. N. and Rave, K. and Heinemann, L. and Chiossi, E. and Krahenbuhl, S. and Dingemanse, J.. (2009) Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. British journal of clinical pharmacology, Vol. 68, no. 4. pp. 502-510.

2003

Spaniol, M. and Kaufmann, P. and Beier, K. and Wuthrich, J. and Torok, M. and Scharnagl, H. and Marz, W. and Krahenbuhl, S.. (2003) Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. Journal of Lipid Research, 44 (1). pp. 144-153.